|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:monoclonal_antibody
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:galcanezumab-gnlm
|
|
gptkbp:class
|
CGRP inhibitors
|
|
gptkbp:clinical_trial
|
gptkb:EVOLVE-1
gptkb:EVOLVE-2
Phase III
chronic migraine
episodic migraine
REGAIN
NCT02614124
NCT02614261
|
|
gptkbp:clinical_use
|
chronic migraine
episodic migraine
|
|
gptkbp:contraindication
|
hypersensitivity to galcanezumab
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:drug_interactions
|
none known
|
|
gptkbp:effective_date
|
2018-09-27
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
auto-injector
pre-filled syringe
|
|
gptkbp:frequency
|
once a month
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Emgality
|
|
gptkbp:ingredients
|
gptkb:galcanezumab
|
|
gptkbp:invention
|
2029
2029-10-18
|
|
gptkbp:label
|
black box warning
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
CGRP receptor antagonist
|
|
gptkbp:patient_education
|
storage instructions
injection technique
when to seek medical help
side effects information
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
long half-life
CGRP inhibition
|
|
gptkbp:price
|
approximately $6,000 per year
|
|
gptkbp:related_products
|
gptkb:Aimovig
gptkb:Ajovy
Emgality (galcanezumab)
|
|
gptkbp:requires
|
gptkb:true
available online
|
|
gptkbp:research_focus
|
neurology
chronic pain management
preventive treatment
headache disorders
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:service_frequency
|
once a month
|
|
gptkbp:side_effect
|
gptkb:depression
anxiety
dizziness
fatigue
nausea
insomnia
constipation
dry mouth
injection site reactions
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
CGRP receptor
|
|
gptkbp:used_for
|
migraine prevention
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly
|
|
gptkbp:bfsLayer
|
4
|